Posts Tagged ‘Neuroendocrine’

Everolimus (Afinitor) Approved for Advanced Unresectable or Metastatic Pancreatic Neuroendocrine Tumors (PNET)

May 7, 2011

On May 5, 2011, the FDA approved everolimus (Afinitor) for treatment of advanced unresectable or metastatic progressive neuroendocrine tumors of pancreatic origin.   

The approval was based on a randomized comparison of everolimus at 10 mg orally/day versus placebo.  The median progression-free survival (PFS) was 11.0 versus 4.6 months, respectively (p<0.001).  This respresents a major advance for patients with this aggressive form of cancer, for which there were few treatment options.